Literature DB >> 10858057

Guideline for prescribing vigabatrin in children has been revised. Vigabatrin Paediatric Advisory Group.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10858057      PMCID： PMC1118061     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Field specific visual evoked potentials for assessment of peripheral field defect in a paediatric population.

Authors:  G F Harding; K A Robertson; I Holliday
Journal:  Suppl Clin Neurophysiol       Date:  2000

2.  Guideline may help in prescribing vigabatrin.

Authors:  R E Appleton
Journal:  BMJ       Date:  1998-11-07

3.  Severe persistent visual field constriction associated with vigabatrin.

Authors:  T Eke; J F Talbot; M C Lawden
Journal:  BMJ       Date:  1997-01-18

4.  Characteristics of a unique visual field defect attributed to vigabatrin.

Authors:  J M Wild; C Martinez; G Reinshagen; G F Harding
Journal:  Epilepsia       Date:  1999-12       Impact factor: 5.864

5.  Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.

Authors:  G L Krauss; M A Johnson; N R Miller
Journal:  Neurology       Date:  1998-03       Impact factor: 9.910
  5 in total
  9 in total

1.  Revised guideline for prescribing vigabatrin in children. Guideline's claim about infantile spasms is not based on appropriate evidence.

Authors:  A L Lux; S W Edwards; J P Osborne; E Hancock; A L Johnson; C R Kennedy; F J O'Callaghan; R W Newton; C M Verity
Journal:  BMJ       Date:  2001-01-27

Review 2.  A risk-benefit assessment of treatments for infantile spasms.

Authors:  R Nabbout
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Recent advances in the pharmacotherapy of infantile spasms.

Authors:  Raili Riikonen
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

Review 4.  Vigabatrin.

Authors:  James W Wheless; R Eugene Ramsay; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 5.  Safety and tolerability of antiepileptic drug treatment in children with epilepsy.

Authors:  Renzo Guerrini; Gaetano Zaccara; Giancarlo la Marca; Anna Rosati
Journal:  Drug Saf       Date:  2012-07-01       Impact factor: 5.606

Review 6.  Use of second-generation antiepileptic drugs in the pediatric population.

Authors:  Allison M Chung; Lea S Eiland
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 7.  Selection criteria for the clinical use of the newer antiepileptic drugs.

Authors:  Charles L P Deckers; P D Knoester; G J de Haan; A Keyser; W O Renier; Y A Hekster
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 8.  Visual field defects with vigabatrin: epidemiology and therapeutic implications.

Authors:  R Kälviäinen; I Nousiainen
Journal:  CNS Drugs       Date:  2001       Impact factor: 6.497

Review 9.  Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options.

Authors:  Shelly Wang; Aria Fallah
Journal:  Neuropsychiatr Dis Treat       Date:  2014-10-23       Impact factor: 2.570
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.